Compass Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
R&D
$56M
D&A
$276K
Operating Income
$-73M
EBITDA
$-73M
Interest Expense
—
Interest Income
$6M
Other Income/Expense
—
Pretax Income
—
Tax Provision
$0
Net Income
$-66M
Operating Margin
-6661.8%
Net Margin
-5808.8%
Effective Tax Rate
—
Deferred Tax Assets
$3M
DTA Valuation Allowance
$79M
Tax Credit Carryforwards
$11M
NOL Carryforwards
$42M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
6.6%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost
—
Revenue YoY Variation
-100.0%
Income YoY Variation
-28.6%